{"id":"W4379508645","doi":"10.1177/17588359231178125","title":"Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy <i>versus</i> endocrine therapy alone in patients with HR+/HER2− early breast cancer","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Genentech; PharmaMar; Novartis Institutes for BioMedical Research; Daewoong Pharmaceutical Company; Astellas Pharma; Eisai; Seagen; Mersana Therapeutics; Mylan; Syndax Pharmaceuticals; Clovis Oncology; Astex Pharmaceuticals; Merck KGaA; Taiho Pharmaceutical; F. Hoffmann-La Roche; Amgen; Radius Health; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Exelixis; Sanofi; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Letrozole; Internal medicine; Breast cancer; Clinical endpoint; Oncology; Anastrozole; Palbociclib; Metastatic breast cancer; Goserelin; Randomization; Cancer; Adjuvant therapy; Clinical trial; Tamoxifen; Gynecology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05800121,0.003357145,0.003894784,0.001853755,0.002583153,0.003267252,0.003411683,0.005822005,0.01785388],"category_scores_gemma":[0.04148613,0.002236635,0.002328791,0.001850667,0.004834429,0.002636118,0.001671823,0.007815777,0.007986967],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002501612,"about_ca_system_score_gemma":0.01003338,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008789632,"about_ca_topic_score_gemma":0.002598859,"domain_scores_codex":[0.9546955,0.03358844,0.002974551,0.003994824,0.003463443,0.001283242],"domain_scores_gemma":[0.9860729,0.0040328,0.002290313,0.001765833,0.002588658,0.003249435],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4644683,0.01217517,0.01318074,0.02352776,0.003882352,0.001896708,0.001669504,0.006055474,0.009857903,0.1028022,0.1472718,0.213212],"study_design_scores_gemma":[0.52255,0.04392109,0.01298686,0.01038778,0.003132429,0.001043893,0.000454838,0.01058373,0.003594934,0.04869352,0.3421746,0.0004762225],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.01051211,0.006296942,0.02217999,0.01112265,0.006684751,0.9250506,0.004355012,0.0003483212,0.01344972],"genre_scores_gemma":[0.02836167,0.001355903,0.02812693,0.01013178,0.001330624,0.9270746,0.001007671,0.00004518596,0.002565662],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.05800121,"threshold_uncertainty_score":0.3067434,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0373529934834873,"score_gpt":0.3836976276393478,"score_spread":0.3463446341558605,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}